Leiden, The Netherlands, April 2, 2013 – ISA Pharmaceuticals B.V., a clinical-stage biopharmaceutical company focusing on rationally designed therapeutic vaccines against cancer and persistent viral infections, today announced that Prof. Cornelis Melief, M.D., will present details on the novel AMPLIVANT™ platform at this year’s American Association for Cancer Research (AACR) Annual Meeting. AMPLIVANT™ is based on a powerful, proprietary toll-like receptor (TLR) ligand improving immunotherapies.

Presentation title: “Synthetic vaccine for immunotherapy of high risk HPV infections“
Symposium: SY27 “New Cancer Vaccines“
Abstract number: SY27-01
Date: April 9, 2013, at 10:40 a.m.
Location: Room 202 at the Washington Convention Center.

The abstract is available at the AACR website www.aacr.org